prolaio eVO2peak Module vs Cardiomo

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Prolaio
VS
by Cardiomo, Inc.

AI Verdict

Tool A, Prolaio's eVO2peak Module, is an FDA-cleared software focused on estimating peak oxygen consumption for cardiovascular research and care using data from third-party sensors. Tool B, Cardiomo, is a medical-grade wearable device and AI platform for continuous, remote heart health monitoring and disease detection. While both operate in cardiology AI and utilize patient data, Prolaio specializes in a specific physiological measurement for clinical evaluation, whereas Cardiomo provides broader, continuous vital sign monitoring and real-time alerts for disease detection.

Choose prolaio eVO2peak Module if…

Choose Prolaio eVO2peak Module if you are a clinician or researcher focused on cardiovascular assessment and require an FDA-cleared software solution to estimate peak oxygen consumption (eVO2peak) using real-world patient data. This tool is ideal for adjunctive aid in clinical evaluation and for high-density, longitudinal data collection in cardiovascular research, leveraging inputs from qualified third-party FDA-cleared wearable medical sensors.

View prolaio eVO2peak Module →

Choose Cardiomo if…

Choose Cardiomo if you need a medical-grade wearable device and an AI-powered platform for continuous, remote heart health monitoring, particularly for detecting cardiovascular diseases and providing timely alerts to users and caregivers. This tool is well-suited for ongoing patient monitoring in cardiology, geriatrics, and internal medicine, offering features like continuous vital sign tracking (ECG, heart rate, respiration, skin temperature) and real-time notifications for potential cardiac events or falls.

View Cardiomo →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature prolaio eVO2peak Module Cardiomo
Pricing Contact for pricing Contact for pricing
Deployment Cloud-based (software-only, processes remote sensor data) Cloud-based with wearable device and mobile app
FDA Status 1 AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiomo

Cardiomo offers a medical-grade wearable device and a mobile app for continuous monitoring, which suggests a more direct and potentially easier user experience for patients. Prolaio's eVO2peak Module is software-only and processes data from third-party sensors, implying a more complex setup and reliance on external devices for data input. Cardiomo's focus on real-time alerts and a user-friendly app for patients and caregivers also points to higher usability for its target audience.

Clinical Value

Tie

Both tools demonstrate strong clinical value within their respective focuses. Prolaio's eVO2peak Module is FDA-cleared and clinically validated for estimating peak oxygen consumption, an important metric in cardiovascular assessment. Cardiomo offers continuous vital sign monitoring and AI-powered disease detection with high accuracy for various cardiovascular events, also undergoing FDA approval. Both are adjunctive aids and not standalone diagnostic tools.

Pricing & Value

Tie

Both companies list 'contact for pricing,' making a direct comparison difficult. Cardiomo previously offered a public price point of $200 with a $10 monthly subscription, which provides some transparency, though current pricing is not available. Without current public pricing for either, it's impossible to definitively determine which offers better value.

Enterprise Readiness

prolaio eVO2peak Module

Prolaio emphasizes its platform for clinical intelligence, integrating medical insights and data analytics to improve clinical development and research. Its FDA clearance and focus on processing data from qualified third-party sensors suggest a more robust and adaptable solution for various enterprise-level healthcare and research settings. Cardiomo, while offering HIPAA compliance and a cloud platform, appears more geared towards direct-to-consumer or smaller-scale remote patient monitoring deployments.

Innovation

Tie

Both tools showcase innovation in their respective areas. Prolaio utilizes a locked deep-learning model to estimate eVO2peak from real-world wearable data, bridging a gap in cardiovascular assessment. Cardiomo integrates a medical-grade wearable with an AI engine for continuous, real-time detection of various cardiovascular diseases and alerts, offering a proactive approach to heart health.

Support & Docs

Tie

Neither the provided structured facts nor web searches offered specific details on the breadth or depth of support and documentation for either Prolaio or Cardiomo. Therefore, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature prolaio eVO2peak Module Cardiomo
Name prolaio eVO2peak Module Cardiomo
Company Prolaio Cardiomo, Inc.
Description Prolaio is a clinical intelligence company that develops FDA-cleared software, such as the eVO2peak Module, to estimate peak oxygen consumption using real-world patient data for cardiovascular research and care. Cardiomo offers a medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers.
Key Features Estimates peak oxygen consumption (eVO2peak); Utilizes demographic data, single-lead ECG, and triaxial accelerometry inputs; Processes data from qualified third-party FDA-cleared wearable medical sensors; Applies a locked deep-learning model for eVO2peak estimation; Provides information as an adjunctive aid in clinical evaluation; Enables high-density, longitudinal data collection; Leverages real-world patient data and insights; Features FDA-cleared software and proprietary algorithms Medical-grade wearable patch; Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature); AI-powered disease detection (arrhythmias, cardiovascular events); Real-time alerts and notifications; Mobile application (Android and iOS); HIPAA-compliant cloud analytics; Fall detection; Long battery life (up to 7-10 days)
Categories Cardiology AI, Clinical Decision Support & Reference Cardiology AI, Wearables & Remote Monitoring (RPM)
Specialties Cardiology, Physical Medicine & Rehab, Sports Medicine Cardiology, Geriatrics, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring prolaio eVO2peak Module and Cardiomo.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Prolaio's eVO2peak Module is a software-only solution that processes data from third-party FDA-cleared wearable sensors, providing information as an adjunctive aid in clinical evaluation. Cardiomo offers a medical-grade wearable device with a mobile app that sends data to a HIPAA-compliant cloud analytics system, and it can send notifications directly to healthcare consultants. Both tools aim to integrate with existing healthcare infrastructure, though specific EHR integration depth would need to be further explored with each vendor.
Prolaio's eVO2peak Module estimates peak oxygen consumption with a Mean Error (Bias) of 1.47 mL/kg/min and a Mean Absolute Error of 4.39 mL/kg/min, validated in a study of 228 patients. Cardiomo claims 99.63% accuracy in detecting cardiac events and providing early alerts, based on its AI engine and biosensors. Medical-grade devices generally show high sensitivity (84-95%) and specificity (up to 93%) for arrhythmia detection.
Prolaio's eVO2peak Module is a software library that processes data, suggesting the learning curve would primarily involve understanding the interpretation of eVO2peak estimates and integrating them into existing clinical evaluation. Cardiomo involves a wearable patch and a mobile app, designed to be user-friendly for continuous monitoring, with its AI analyzing data and sending notifications. The ease of learning for AI-guided tools in cardiology is an active area of study, with some research suggesting AI can shorten training for image acquisition.
Prolaio emphasizes its commitment to quality systems and continuous improvement, and its platform integrates medical insights and data analytics. Cardiomo's system is designed to send real-time alerts and notifications to users, relatives, and care providers, and it aims to reduce the distance between patient and practitioner. Specific details on support quality, such as dedicated account managers or training programs, would require direct inquiry with each company.
Prolaio states its commitment to safeguarding data integrity, privacy, and cybersecurity, and its cybersecurity testing was conducted under FDA's 2023 guidance, including encryption, access control, input validation, and logging. Cardiomo utilizes a HIPAA-compliant cloud analytics system. Generally, robust cloud security postures beyond HIPAA include Zero Trust Architecture, continuous monitoring, regular penetration testing, and encryption of data at rest and in transit.
Prolaio's approach involves high-density, longitudinal data collection leveraging real-world patient data, which could support multi-site rollouts by providing consistent data collection and analysis. Cardiomo's cloud-based platform and wearable device with a mobile app are inherently designed for remote monitoring, suggesting scalability for broader deployment. Successful multi-site cardiology workflow management often requires shared protocols and unified billing.
Prolaio's eVO2peak Module provides an estimate of peak oxygen consumption, which is an adjunctive aid in the clinical evaluation of adult patients for whom VO2 Peak cardiopulmonary functional testing is desired. Cardiomo offers continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature) and AI-powered disease detection for arrhythmias and cardiovascular events, providing real-time alerts and event prediction for timely intervention.

Backers

Who funded each tool's parent company.

Cardiomo

AI Tool Finder
AI-powered search. Results may not be comprehensive.